The two positions I'm in after researching every company, of the 308 biotech companies, that sells shares for under $5. NUVO (3.6) First drug Partnered with Amgen About to complete phase 2 in December or early January Other drugs in the pipeline. Nearing a buy oportunity. Has an upward trend. VRA (.25 per share) Has created the best drug to treat Hepatitus C. This drug is natrual and better than the competition. 3% of the world is infected with HC. The drug is currently being sold in Sweden and Mexico. The drug is being considered for sales in China and Chile and everywhere else. It's only a matter of time until the drug becomes the primary treatment for HC. The company has created, and is articulating, a novel and better way to manufacture drugs. If the company succeeds in this transgenic technology it will manufacture drugs for many biotech companies. Yet the company will become hugely successful from sales of the HC drug anyway. It seems to me that the company's dramatic stock price increase is going to happen in a matter of time.